Pancreatic cancer treatment depends mainly on whether the tumour can be completely removed by surgery.

• Resectable: the tumour can be removed. Treatment is usually surgery, such as the Whipple procedure for tumours in the head of the pancreas, combined with chemotherapy, most often mFOLFIRINOX.
• Borderline resectable or locally advanced: the tumour involves nearby blood vessels. Chemotherapy is usually given first, and some patients can then have surgery.
• Metastatic: the cancer has spread. Treatment uses chemotherapy combinations to control the cancer and relieve symptoms, with targeted therapy for a small number of patients with specific gene changes.

Surgeon and hospital experience matter a great deal. From 2025, German hospitals must perform at least 20 complex pancreatic operations a year to be allowed to perform them. Heidelberg University Hospital's European Pancreas Center performs more than 700 pancreatic operations a year and handles enquiries from abroad.

Estimated prices for the Whipple procedure in Germany are around €26,000 to €42,000.

This guide explains how treatment is chosen, what surgery involves, current drug treatments, what to watch for, estimated costs, and how to get a second opinion.

What Is Pancreatic Cancer?

The pancreas is a gland located behind the stomach that plays an important role in digestion and blood sugar regulation. It produces digestive enzymes that help break down food and hormones such as insulin, which helps control blood glucose levels.

Pancreatic cancer occurs when abnormal cells in the pancreas grow uncontrollably and form a tumour. It can develop in different types of pancreatic cells, but pancreatic ductal adenocarcinoma (PDAC) is the most common type and accounts for the majority of pancreatic cancers. This page focuses primarily on pancreatic ductal adenocarcinoma.

Symptoms often appear late. They include:

• jaundice (yellow skin or eyes, dark urine, pale stools, itching)
• upper abdominal or back pain
• weight loss and loss of appetite
• new-onset diabetes
• fatty, pale stools

Diagnosis, Staging and Resectability

Accurate staging decides whether surgery is possible. German centres typically use:

• Contrast-enhanced CT with a dedicated pancreas protocol. This is the key test for tumour extent and blood vessel involvement.
• MRI, particularly for small liver metastases.
• Endoscopic ultrasound (EUS) with biopsy, to confirm the diagnosis when needed.
• CA 19-9 blood test, to help assess the tumour and monitor response.
• ERCP with stenting, if jaundice needs relief.
• Germline genetic testing and tumour molecular testing (BRCA1/2, PALB2, MSI/dMMR, KRAS), which can open specific treatment options and affect family members.

Resectability categories

Second opinions matter. Resectability judgments differ between centres. Some tumours called inoperable elsewhere can be removed at very experienced pancreatic surgery centres, sometimes after chemotherapy. A remote review of your CT scans (the images, not just the report) by a high-volume centre is worthwhile.

Surgery for Pancreatic Cancer

Surgery is the only treatment that offers a chance of cure. It is major surgery and should be done at a high-volume centre.

• Whipple procedure (pancreaticoduodenectomy). For tumours in the head of the pancreas. It removes the pancreatic head, duodenum, bile duct, and gallbladder, and sometimes part of the stomach. The digestive tract is then reconnected.
• Distal pancreatectomy. For tumours in the body or tail. It is usually done with removal of the spleen and can often be performed laparoscopically or robotically.
• Total pancreatectomy. Removes the whole pancreas when needed. It always causes diabetes and requires lifelong enzyme replacement.
• Vascular resection. In experienced centres, surgeons can remove affected sections of the vein, and occasionally the artery, and reconstruct them, allowing more patients to have surgery.

Minimally invasive and robotic surgery is increasingly used, especially for distal pancreatectomy. The surgeon's experience matters more than the technique.

Risks include:

• leakage from the pancreatic junction (pancreatic fistula)
• delayed stomach emptying
• bleeding and infection

Mortality after pancreatic surgery is lower in high-volume hospitals. German health services data cited in guideline discussions showed a mortality rate of about 6.5% in high-volume centres, compared with 11.5% in low-volume ones.

Chemotherapy and Other Drug Treatments

Around surgery

• After surgery (adjuvant): mFOLFIRINOX (a combination of 5-FU, leucovorin, irinotecan and oxaliplatin) is standard for fit patients. Gemcitabine-based options, such as gemcitabine with capecitabine, are used for patients less able to tolerate it. Adjuvant chemotherapy usually lasts about six months.
• Before surgery (neoadjuvant): used for borderline resectable and locally advanced tumours, and increasingly considered for resectable tumours.

Metastatic pancreatic cancer

First-line options for fit patients include:

• FOLFIRINOX
• NALIRIFOX (liposomal irinotecan with oxaliplatin, 5-FU and leucovorin), approved in the EU in March 2024 as a first-line treatment
• gemcitabine with nab-paclitaxel

Gemcitabine alone may suit less fit patients.

Targeted and precision treatments (small groups of patients)

• Olaparib is a maintenance tablet for patients with a germline BRCA mutation whose cancer has not progressed after platinum chemotherapy. It was approved in the EU in 2020. It delays progression but has not been shown to extend overall survival.
• Immunotherapy (checkpoint inhibitors) helps only the very small number of patients whose tumours are MSI-high or mismatch repair deficient. It is not effective for most pancreatic cancers.
• Other rare targets, such as NTRK fusions in KRAS wild-type tumours, may have targeted options or clinical trials.

This is why molecular testing is worthwhile, even though most patients will not have a targetable change.

Radiotherapy

Radiotherapy, including stereotactic body radiotherapy (SBRT), may be used in selected patients with locally advanced disease, or to relieve pain. Its survival benefit is less clear than that of chemotherapy.

Proton therapy is offered at some German centres for selected pancreatic tumours. It is not a standard treatment, and evidence of benefit over photon radiotherapy is limited.

NanoKnife and Other Local Ablation: What to Know?

Irreversible electroporation (IRE, NanoKnife) uses electrical pulses to damage tumour cells. It is sometimes offered for locally advanced tumours that cannot be removed.

It remains experimental. The evidence comes mainly from non-randomised studies, and randomised trials are still ongoing. It carries risks of serious complications. If offered IRE, ask:

• whether it is being done within a clinical trial or registry
• how many procedures the team has performed
• what the complication rate is

It should follow effective chemotherapy, not replace it.

Unproven Treatments: A Warning

Some clinics and websites promote dendritic cell vaccines, hyperthermia or other "immune" therapies for pancreatic cancer, often at high cost. These are not approved standard treatments.

The European Medicines Agency has warned that unregulated cell therapies are being sold to patients across Europe with little or no evidence. Ask whether any treatment offered is EMA-approved or part of a registered clinical trial.

Supportive Care: Important in Every Stage

• Jaundice. A stent placed during ERCP relieves bile duct blockage.
• Digestion. Pancreatic enzyme replacement capsules taken with meals help with weight loss and fatty stools.
• Diabetes. Blood sugar is monitored, especially after surgery.
• Pain. Medicines and sometimes a nerve block (coeliac plexus block).
• Nutrition and weight. Dietitian support throughout treatment.
• Blood clots. These are more common in pancreatic cancer, and preventive treatment may be advised.
• Palliative care. Should start early alongside cancer treatment.

What Treatment in Germany Involves for International Patients?

Hospital quality signals

• Minimum volume rule. Since 2025, German hospitals must perform at least 20 complex pancreatic operations a year to offer them. An insurer's 2026 transparency map reported 286 hospital sites meeting this threshold, down from 405 in 2023. German surgical and guideline bodies have debated even higher thresholds.
• DKG-certified pancreatic cancer centres (Pankreaskarzinomzentren), usually within visceral oncology centres. These are listed on OncoMap.

Typical time in Germany

Hospitals for Pancreatic Cancer Treatment in Germany

Check whether a hospital has:

• a high annual volume of pancreatic resections, well above the legal minimum of 20
• DKG certification as a pancreatic cancer centre
• experience with vascular resection and surgery after chemotherapy
• pancreas-specific radiology and interventional endoscopy (EUS and ERCP)
• molecular testing and clinical trials
• nutrition and palliative care support
• an international patient office that can provide written estimates and interpreters

The hospitals below are examples with verified information. This is not a ranking or endorsement.

Certifications, specialists and international services change. Vaidam can confirm current details for the hospitals you are considering.

Cost of Pancreatic Cancer Treatment in Germany

No single fixed price applies. Cost depends on the stage, the treatment plan, the length of stay and the hospital. Estimated prices for the Whipple procedure in Germany are around €26,000 to €42,000.

What affects the total cost?

How International Patients Can Prepare?

Medical documents to gather

• CT scans with a pancreas protocol, if available, as images on disc or download link, ideally from the last 4 weeks. MRI if done.
• Biopsy or pathology report, and tissue blocks if requested.
• Blood tests: CA 19-9, bilirubin, liver and kidney function, blood count.
• ERCP or stent reports, if a stent has been placed.
• Genetic or molecular test results, if done.
• Chemotherapy records: regimen, cycles, dates and response.
• Weight history, current medications and other conditions, including diabetes.

Reports in languages other than English or German may need translation.

Travel and administrative documents

Visa. Most non-EU patients need a visa for medical treatment. Applications usually need the hospital's invitation letter with a cost estimate, proof of funds and health insurance.

Other items to arrange:

• proof of funds or an insurer's guarantee of payment
• accommodation near the hospital
• a companion

Timing. Pancreatic cancer can progress quickly. Arrange the remote review and travel promptly, and make sure jaundice and any infection are controlled before flying.

Questions to Ask the Pancreatic Team

1. Is my tumour resectable, borderline resectable, locally advanced or metastatic?
2. Could chemotherapy first make surgery possible?
3. How many pancreatic resections does your centre perform each year?
4. Do you perform vascular resections when needed?
5. Which chemotherapy do you recommend before or after surgery?
6. Should I have germline genetic testing and tumour molecular testing?
7. Am I eligible for any clinical trials?
8. How long will I stay in Germany, and can chemotherapy continue at home?
9. How will jaundice, digestion and diabetes be managed?
10. What does the cost estimate include and exclude?

Recovery After Pancreatic Surgery

• Hospital stay: often around one to two weeks, longer if complications occur.
• Eating: gradual return to normal meals. Delayed stomach emptying may slow this.
• Enzymes: many patients need pancreatic enzyme capsules with meals.
• Diabetes: may develop or worsen, especially after large resections.
• Strength: it can take several weeks to months to recover before or during adjuvant chemotherapy.
• Follow-up: CT scans and CA 19-9 tests at intervals set by the team.

Outlook

Pancreatic cancer has a lower survival rate than most cancers, mainly because it is often diagnosed late. The figures below are US data from the American Cancer Society, based on people diagnosed between 2015 and 2021.

Source: American Cancer Society, based on SEER data for people diagnosed 2015–2021.

How to read these figures:

• They are averages for large groups and cannot predict an individual outcome.
• People who complete surgery and adjuvant chemotherapy do better than the stage averages suggest.
• The figures predate some newer treatments and are not specific to treatment in Germany.

How Vaidam Helps International Patients?

Vaidam Health is a medical travel facilitation service. It does not provide medical treatment itself. When you contact Vaidam, you are assigned a case manager who can:

• share your scans and records with high-volume German pancreatic centres for a resectability review
• obtain a medical opinion and written cost estimate, usually within 48 hours
• help you compare hospitals against the criteria above
• help with visa documentation and the hospital's invitation letter
• arrange accommodation near the hospital, airport transfers and appointment scheduling
• arrange interpreters (in Germany, interpreter services are chargeable)
• stay in contact after you return home to help with follow-up consultations and reports

Vaidam states that its services are free for patients and do not increase the hospital bill. Treatment decisions remain with your doctors.

Frequently Asked Questions

1. How much does pancreatic cancer treatment cost in Germany?

Estimated prices for the Whipple procedure are about €26,000 to €42,000. A pancreatic cancer diagnostic work-up can be about €3,200, and a chemotherapy programme can be about €7,400. The final cost depends on the treatment plan and length of stay.

2. My tumour was called inoperable. Can a German centre operate?

Sometimes. High-volume centres may operate on tumours involving blood vessels, often after chemotherapy. A remote review of your CT images by an experienced pancreatic centre can give a second opinion on resectability.

3. What is the Whipple procedure?

It removes the head of the pancreas, the duodenum, the bile duct and gallbladder, and sometimes part of the stomach, then reconnects the digestive tract. It is used for tumours in the head of the pancreas.

4. Why does hospital volume matter?

Complex pancreatic surgery is safer in high-volume hospitals. German data showed lower mortality in high-volume centres. Since 2025, German hospitals must perform at least 20 complex pancreatic operations a year to perform them.

5. What chemotherapy is used for pancreatic cancer?

mFOLFIRINOX is standard after surgery for fit patients. For metastatic disease, options include FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel. Chemotherapy is also given before surgery for borderline and locally advanced tumours.

6. Does immunotherapy work for pancreatic cancer?

Only for a very small group whose tumours are MSI-high or mismatch repair deficient. For most pancreatic cancers, checkpoint inhibitors are not effective. Molecular testing identifies who might benefit.

7. Is NanoKnife (IRE) a good option?

It is still experimental, with mainly non-randomised evidence and a risk of serious complications. If offered, ask whether it is part of a trial or registry, and how experienced the team is.

8. Is olaparib used for pancreatic cancer?

Yes, as maintenance for patients with a germline BRCA mutation whose cancer has not progressed on platinum chemotherapy. It delays progression but has not been shown to extend overall survival.

9. How long will I need to stay in Germany?

For a Whipple procedure, plan for about two to three weeks, longer if complications occur. Chemotherapy lasting several months can often continue at home under a plan agreed with the German team.

10. Is dendritic cell therapy an option?

It is not an approved standard treatment for pancreatic cancer. The European Medicines Agency has warned about unregulated cell therapies sold in Europe. Ask whether any treatment offered is EMA-approved or part of a registered trial.

Sources

• Heidelberg University Hospital: European Pancreas Center (surgical volume, services, international enquiries).
• Gelbe Liste: disputed points in the pancreatic cancer guideline (minimum volumes, German mortality data by hospital volume).
• Medconweb: AOK Mindestmengen-Transparenzkarte 2026 (minimum of 20 procedures since 2025; 286 hospital sites).
• Leitlinienprogramm Onkologie: S3-Leitlinie Exokrines Pankreaskarzinom, Version 3.1 (2024), AWMF 032-010OL. The Springer 2024 summary could not be accessed because the site limited requests.
• Digestive Cancers Europe: EMA approval of NALIRIFOX as first-line treatment for metastatic pancreatic cancer (March 2024).
• AstraZeneca: Lynparza approved in the EU for germline BRCA-mutated metastatic pancreatic cancer (2020). Golan T et al. POLO trial, NEJM 2019.
• Pharmaceutical Technology: EMA warning on unregulated cell therapies sold in Europe.
• American Cancer Society: Pancreatic cancer survival rates (SEER 2015–2021).
• OncoMap / OnkoZert: certified pancreatic cancer centres.
• Vaidam.com homepage (service descriptions).